image

GET READY FOR THE ‘SHROOM RUSH

Former executives from some of Canada’s largest cannabis companies are pioneering the psychedelic drug industry.

Toronto-based MindMed plans to test microdosed LSD as a treatment for ADHD and a molecule derived from the psychoactive compound Ibogaine as a treatment for opioid addiction. (Ibogaine is a psychoactive compound found in Iboga, a shrub native to West Africa.)
Globe and Mail

  • MindMed has raised C$6.2M from investors including former Canopy Growth CEO Bruce Linton and “Shark Tank’s” Kevin O’Leary.